The dominant catalyst driving the sharp upward momentum in argenx SE is the announcement of positive topline results from its landmark Phase 3 ALKIVIA study. The trial evaluated VYVGART Hytrulo in adult patients suffering from autoimmune myositis and successfully achieved its primary endpoint with high statistical significance in the combined patient population. Efgartigimod demonstrated robust, rapid, and sustained clinical improvements in disease activity over a 52-week period compared to placebo, even alongside corticosteroid tapering. Importantly, this marks the first Phase 3 trial to demonstrate statistically significant and clinically meaningful efficacy in immune-mediated necrotizing myopathy, a debilitating disease subtype…